This study is for people with advanced lung cancer called non-squamous non-small cell lung cancer (NSCLC) that doesn't have certain gene changes. It compares two treatments: datopotamab deruxtecan (Dato-DXd) and docetaxel, which are both drugs used for cancer treatment. The study aims to see which treatment works better and is safer. To be part of this study, participants must have already tried other cancer treatments and have specific lung cancer that tests positive for a protein called TROP2.
- Participants will need to provide a tumor sample for testing.
- The study involves multiple visits to the clinic for treatment and check-ups.
- Check if you qualify based on your medical history and current health status.
How understandable was the trial content above?
Hard to understand
Easy to understand